Article3 Biotech2026
Rufigallol attenuates splenic damage caused by STZ by targeting oxidative stress, inflammation, and the apoptosis pathway.
Article in 3 Biotech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both. It is associated with progressive organ damage, including splenic injury driven by oxidative stress, inflammation, and enhanced apoptosis. We investigated the protective effects of rufigallol against streptozotocin (STZ)-induced splenic damage in diabetic rats. Diabetes was induced in Wistar rats by a single intraperitoneal injection of STZ (50 mg/kg). Diabetic rats received oral rufigallol (10 or 20 mg/kg/day) for 8 weeks. Fasting blood glucose, spleen weight, hematological parameters, oxidative stress markers (MDA, NO, SOD, CAT, and GSH), inflammatory mediators (IL-1β, IL-2, IL-6, IL-4, TNF-α, IFN-γ, and NF-κB), apoptosis-related proteins (Bax, Bcl-2, and caspase-3), and splenic histopathology were evaluated. STZ administration produced persistent hyperglycemia, reduced spleen weight, anemia, leukocytosis, thrombocytopenia, elevated MDA and NO levels, depletion of SOD, CAT, and GSH, increased concentrations of pro-inflammatory cytokines and NF-κB, upregulated Bax and caspase-3 expression, reduced Bcl-2 expression, and marked histopathological alterations in splenic tissue. Rufigallol treatment significantly lowered fasting blood glucose, improved spleen weight and hematological indices, restored antioxidant defenses, reduced lipid peroxidation and nitric oxide production, suppressed inflammatory cytokines and NF-κB activation, decreased Bax and caspase-3 expression while increasing Bcl-2 expression, and markedly improved splenic histological architecture. The protective effects were consistently greater in the 20 mg/kg group than in the 10 mg/kg group. Our findings suggest that rufigallol attenuated STZ-induced splenic injury by reducing oxidative stress, suppressing inflammatory responses, and normalizing apoptotic markers (Bax, Bcl-2, and caspase-3), thereby preserving splenic structure and function in diabetic rats. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13205-026-05047-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.